Funding: HMNC and the Long Road to Precision Psychiatry
Funding: HMNC and the Long Road to Precision Psychiatry.
HMNC Brain Health
Private
HMNC Brain Health is a Munich-based clinical-stage biopharmaceutical company developing personalized precision psychiatry treatments powered by AI and pharmacogenomics. Its pipeline includes two lead depression programs, one of which is an oral esketamine formulation being developed as a more convenient alternative to Johnson & Johnson's Spravato, and a separate novel mechanism in treatment-resistant depression. The company is leveraging companion-diagnostic and digital-phenotyping tools to stratify patients and improve response rates in major depressive disorder.
Company Info
Sector:Biotechnology / CNS (Precision Psychiatry)
Headquarters:Munich, Bavaria, Germany
Founded:2018
Website:www.hmnc-brainhealth.com/
Funding Round:Series B (June 2026, $50M)
Total Funding:~$80M+ cumulative venture-backed funding (Series A + Series B + earlier grants)
Funding & Investor Relations
Notable Investors
- Headquartered investors include family offices and European life-sciences venture capital; full investor list not publicly disclosed
IPO Outlook / Plans
None publicly disclosed; clinical-stage European CNS biotech.
Upcoming Milestones & Key Dates
H2 2026
Clinical Trial
Initiation of HMNC-OES Phase 3 enabling studies
Late 2026
Clinical Trial
First AI-stratified Phase 2 efficacy readout in MDD
Clinical Development Pipeline
HMNC-OES (oral esketamine)
Target: NMDA receptor antagonist (oral formulation, Spravato challenger)HMNC-Dep1 (undisclosed novel mechanism)
Target: Undisclosed; AI-discovered mechanism with companion diagnosticHMNC diagnostic platform
Target: AI-driven digital phenotyping and pharmacogenomicsRecent News
Funding: HMNC and the Long Road to Precision Psychiatry
Funding: HMNC and the Long Road to Precision Psychiatry.
Leadership Team
Dr. Heinz Kurz
Co-Founder and Chief Executive Officer
Dr. Jan Petry
Chief Medical Officer